Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 20/20 | 0.71 |
| ▸ | ITGB3 | P05106 | 18/20 | 0.71 |
| ▸ | ITGB6 | P18564 | 7/20 | 0.58 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.57 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.57 |
| ▸ | ITGB5 | P18084 | 5/20 | 0.56 |
| ▸ | ITGB8 | P26012 | 5/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26480263 | 0.93 | ITGAV (0.69) | ITGAVITGB3ITGB6ITGB1ITGA4 | |
| SCHEMBL24363125 | 0.88 | ITGAV (0.75) | ITGAVITGB3ITGB6ITGB1ITGA4 | |
| SCHEMBL22029428 | 0.88 | ITGAV (0.75) | ITGAVITGB3ITGB6ITGB1ITGA4 | |
| SCHEMBL24336626 | 0.86 | ITGAV (0.67) | ITGAVITGB3ITGB6ITGB1ITGA4 | |
| SCHEMBL21706034 | 0.86 | ITGAV (0.75) | ITGAVITGB3ITGB6ITGB1ITGA4 | |
| SCHEMBL22029478 | 0.86 | ITGAV (0.75) | ITGAVITGB3ITGB6ITGB1ITGA4 | |
| SCHEMBL24362780 | 0.85 | ITGB3 (0.83) | ITGAVITGB3ITGB6ITGB1ITGA4 | |
| SCHEMBL22029431 | 0.85 | ITGB3 (0.83) | ITGAVITGB3ITGB6ITGB1ITGA4 | |
| SCHEMBL21705572 | 0.85 | ITGAV (0.71) | ITGAVITGB3ITGB6ITGB1ITGA4 | |
| SCHEMBL6421618 | 0.83 | ITGB3 (1.00) | ITGAVITGB3ITGB6ITGB5ITGB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11643393-B2 | Integrin antagonists | THE GENERAL HOSPITAL CORPORATION (US) | 2023-05-09 | — | — | US | disclosed |
| US-20220081398-A1 | Integrin Antagonists | THE GENERAL HOSPITAL CORPORATION | 2022-03-17 | — | — | US | disclosed |
| WO-2020033724-A1 | INTEGRIN ANTAGONISTS | THE GENERAL HOSPITAL CORPORATION (US) | 2020-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220081398-A1 | Integrin Antagonists | ITGA2B, ITGA2, ITGB2 | ITGAV 5/4885ITGB3 9/4885ITGB6 16/4885 |
| US-11643393-B2 | Integrin antagonists | ITGA2B, ITGA2, ITGB2 | ITGAV 5/4885ITGB3 9/4885ITGB6 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.